These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33309946)

  • 21. A computer program for designing clinical trials with arbitrary survival curves and group sequential testing.
    Halpern J; Brown BW
    Control Clin Trials; 1993 Apr; 14(2):109-22. PubMed ID: 8500301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On testing simultaneously non-inferiority in two multiple primary endpoints and superiority in at least one of them.
    Röhmel J; Gerlinger C; Benda N; Läuter J
    Biom J; 2006 Dec; 48(6):916-33. PubMed ID: 17240652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate.
    Lehmacher W; Wassmer G; Reitmeir P
    Biometrics; 1991 Jun; 47(2):511-21. PubMed ID: 1912258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials.
    Hartung J
    Biom J; 2006 Aug; 48(4):521-36. PubMed ID: 16972703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Group sequential design for historical control trials using error spending functions.
    Wu J; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):351-363. PubMed ID: 31718458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
    Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
    Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple testing procedures in two pivotal clinical trials for approval of a new pharmaceutical product.
    Wiens BL
    J Biopharm Stat; 2011 Jul; 21(4):669-81. PubMed ID: 21516563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CP function: an alpha spending function based on conditional power.
    Jiang Z; Wang L; Li C; Xia J; Wang W
    Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A group sequential test for treatment effect based on the Fine-Gray model.
    Martens MJ; Logan BR
    Biometrics; 2018 Sep; 74(3):1006-1013. PubMed ID: 29534294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-stage designs with small sample sizes.
    Kieser M; Rauch G; Pilz M
    J Biopharm Stat; 2023 Jan; 33(1):53-59. PubMed ID: 35612521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conditional power calculations for early acceptance of H0 embedded in sequential tests.
    Betensky RA
    Stat Med; 1997 Feb; 16(4):465-77. PubMed ID: 9044533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.